Can-Fite BioPharma Ltd.
CANF- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001536196
No open-market purchases or sales by Can-Fite BioPharma Ltd. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $149.1K in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Can-Fite BioPharma Ltd. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 12 | 1 | 11 | 0 |
| Shares | 495.6K | 1.10K | 427.8K | −66.7K (−13.5%) |
| Value | $380.5K | $847 | $262.2K | −$117.4K (−30.9%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (1)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BNP Paribas Arbitrage, SA | 400 | $245 | 0.00% |
Sold out (1)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Virtu Financial LLC | 28,771 | $22.0K |
Not filed for Q4 2022 yet (1)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| American Portfolios Advisors | 1,100 | $847 |